Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports - Reuters
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQUkdBem1IX3AtekZzbllhUEZyTU9HQU1RY1AxRF9ZSnNoNlAybXNmcnFnTDZ3X3RJWDQ4bXNlNERLeWlUNy02dFNfQl9BbXBKZmRHVXRpdi1oMXltUF9qNVB2NEQ0WDJJbmdXSDJ6WGJDUzR2c0t6MDVycnhKOWRCckwySkc1SjN6d1FZNWpzZW5nSnRHRWl4M3dtaXNMeGN1d0RuMVJsTjR1R25EYWhsbmR5Rk9ndzdhTzJuVzN4QUg2SFR5cDZPbUxDVHhjVmhWaDlaTGI0Z1NwTUhGTlE?oc=5" target="_blank">Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Experimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMWalgreens-owner Sycamore nears $9 billion sale of Boots, WSJ reports - reuters.com
Walgreens-owner Sycamore nears $9 billion sale of Boots, WSJ reports reuters.com
September 30, 2026 at 08:14 PMUS FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMAstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters
October 2, 2026 at 06:58 AMAstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up Reuters
September 28, 2026 at 10:15 PMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PM